Table 3.
Resource inputs
| Parameter | Value or probability | Unit cost | Source |
|---|---|---|---|
| Drug acquisition | Cost per day (£) | ||
| First-line pharmacotherapy | – | ||
| Mirabegron 50 mg | – | 0.97 | BNF 71 [23] |
| Fesoterodine 4/8 mg | – | 0.92 | BNF 71 [23] |
| Oxybutynin ER 5 mg | – | 0.46 | BNF 71 [23] |
| Oxybutynin IR 5 mg | – | 0.07 | BNF 71 [23] |
| Solifenacin 5/10 mga | – | 1.00 | BNF 71 [23] |
| Tolterodine ER 4 mg | – | 0.92 | BNF 71 [23] |
| Tolterodine IR 4 mg | – | 0.09 | BNF 71 [23] |
| Trospium ER 60 mg | – | 0.82 | BNF 71 [23] |
| Trospium IR 40 mg | – | 0.83 | BNF 71 [23] |
| Darifenacin 7.5 mg | – | 0.91 | BNF 71 [23] |
| Flavoxate 600 mg | – | 0.39 | BNF 71 [23] |
| Second-line pharmacotherapyb | – | 0.64 | BNF 71 [23], Astellas [24] |
| Surgical operationsc | 0.01% | 1242.59 | |
| Visits/test | |||
| GP | 1 | 46.89 | Nazir et al. [19]; PSSRU [21] |
| Urologist | 1.5 | 102.16 | Nazir et al. [19]; UK Department of Health |
| Urodynamic test | 1 | 282.00 | Nazir et al. [19]; South Devon Healthcare [30] |
| Pads | Cost per pad (£) | ||
| On treatment | 2.5/day | 0.25 | Nazir et al. [19]; Incontinence Direct [31] |
| Off treatment | 5.5/day | 0.25 | Nazir et al. [19]; Incontinence Direct [31] |
| Co-morbidities | |||
| Depression | 19.0%d | 99.10 | Arlandis-Guzman et al. [25]; Irwin et al. [6] |
| UTI | 30.7%d | 2.79 | Arlandis-Guzman et al. [25]; Irwin et al. [6] |
All doses reported are the total dose per day
BNF British National Formulary, ER extended release, GP general practitioner, IR immediate release, OAB overactive bladder, UTI urinary tract infection
aWeighted average of solifenacin 5 mg (70%) and 10 mg (30%); unit costs of 30 tablet packs of £27.62 and £35.91, respectively
bWeighted cost based on market share of oral therapies for OAB
cWeighted cost based on a 50:50 ratio of onabotulinumtoxinA and sacral nerve stimulation
d6-month probability; unit costs based on 2005 monthly costs, converted to 2015 values using the UK forex exchange rate (as of October 2015)